Chemotherapy-induced peripheral neuropathy (CIPN) - Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report - 2025 To 2035

Chemotherapy-Induced Peripheral Neuropathy (CIPN) Market Outlook

Thelansis's "Chemotherapy-Induced Peripheral Neuropathy (CIPN) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report - 2025 To 2035" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Chemotherapy-Induced Peripheral Neuropathy treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Chemotherapy-Induced Peripheral Neuropathy (CIPN) Overview

Chemotherapy-induced peripheral neuropathy (CIPN) is a prevalent and often dose-limiting toxicity associated with neurotoxic anticancer agents, particularly taxanes, platinum compounds, and vinca alkaloids. It arises from multifactorial damage to the peripheral nervous system, including axonal degeneration, mitochondrial dysfunction, and direct injury to dorsal root ganglia, which are highly susceptible due to their metabolic activity and permeable blood-nerve barrier.

Clinically, CIPN presents as a symmetric sensory neuropathy in a "glove-and-stocking" distribution, characterized by numbness, tingling (paresthesia), and burning pain. A notable feature is the "coasting" phenomenon, where symptoms continue to worsen even after cessation of chemotherapy.

Risk factors include cumulative drug exposure, advanced age, and comorbidities such as diabetes. Currently, there are no approved therapies for prevention, and management remains symptomatic. Duloxetine (SNRI) is the only evidence-based pharmacologic option, while severe neuropathy often necessitates dose reduction or discontinuation of chemotherapy, impacting cancer treatment outcomes.

Key Highlights

• CIPN is a common, dose-limiting toxicity impacting cancer treatment and patient quality of life
• US cancer incidence (proxy population) expected to grow from ~1.74M to ~1.83M (~0.5% CAGR)

Market Overview

• Germany market projected to grow from ~$170M to ~$290M (~5-6% CAGR)
• Growth driven by supportive care demand and unmet need, with no approved preventive therapies

Insights driven by robust research, including:

• In-depth interviews with leading KOLs and payers
• Physician surveys
• RWE analysis for claims and EHR datasets
• Secondary research (e.g., peer-reviewed journal articles, third-party research databases)

Deliverables format and updates*:

• Detailed Report (PDF)
• Market Forecast Model (MS Excel-based automated dashboard)
• Epidemiology (MS Excel; interactive tool)
• Executive Insights (PowerPoint presentation)
• Others: regular updates, customizations, consultant support
• As per Thelansis's policy, we ensure that we include all the recent updates before releasing the report content and market model.

Salient features of Market Forecast model:

• 10-year market forecast (2025-2035)
• Bottom-up patient-based market forecasts validated through the top-down sales methodology
• Covers clinically and commercially-relevant patient populations/ line of therapies
• Annualized drug-level sales and patient share projections
• Utilizes our proprietary Epilansis and Analog tool (e.g., drug uptake and erosion) datasets and conjoint analysis approach
• Detailed methodology/sources & assumptions
• Graphical and tabular outputs
• Users can customize the model based on requirements

Key business questions answered:

• How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)?
• How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments?
• What is the 10-year market outlook for sales and patient share?
• Which events will have the greatest impact on the market's trajectory?
• What insights do interviewed experts provide on current and emerging treatments?
• Which pipeline products show the most promise, and what is their potential for launch and future positioning?
• What are the key unmet needs and KOL expectations for target profiles?
• What key regulatory and payer requirements must be met to secure drug approval and favorable market access?

Countries Covered

• G8
  • United States
  • EU5
    • France
    • Germany
    • Italy
    • Spain
    • U.K.
  • Japan
  • China

Apart from the G8 Market, adding any additional country data to the dashboard/report will cost USD 1,750 per country

Companies Mentioned

• Tarian Pharma
• Ono Pharmaceutical Co. Ltd
• Akeso
• Qilu Pharmaceutical Co., Ltd.
• VM Therapeutics LLC
• Dogwood Therapeutics Inc.